These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20664052)

  • 21. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The immunological phenotype and proliferative activity of the tumor lymphocytes in multiple myeloma].
    Golenkov AK; Nazarova IN; Sarycheva TG; Miterev GIu; Kozinets GI
    Ter Arkh; 1993; 65(7):38-41. PubMed ID: 8211777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
    Colucci S; Brunetti G; Rizzi R; Zonno A; Mori G; Colaianni G; Del Prete D; Faccio R; Liso A; Capalbo S; Liso V; Zallone A; Grano M
    Blood; 2004 Dec; 104(12):3722-30. PubMed ID: 15308561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma.
    Rossi JF; Chappard D; Marcelli C; Laplante J; Commes T; Baldet P; Janbon C; Jourdan J; Alexandre C; Bataille R
    Br J Haematol; 1990 Dec; 76(4):469-75. PubMed ID: 2265108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
    Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
    Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production of interleukin-1 by bone marrow myeloma cells.
    Cozzolino F; Torcia M; Aldinucci D; Rubartelli A; Miliani A; Shaw AR; Lansdorp PM; Di Guglielmo R
    Blood; 1989 Jul; 74(1):380-7. PubMed ID: 2665838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Imbalance of treg/th17 in bone marrow of patients with multiple myeloma].
    Xing J; Lu G; Liu GQ; Xu M; Zhao X; Han F; Wang L; Ding HF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1321-5. PubMed ID: 25338581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients.
    Hidalgo-Lopez JE; Higa MG; Ferrian S; Lin P; Blando J; Medeiros LJ; Bueso-Ramos CE
    Ann Diagn Pathol; 2019 Jun; 40():174-175. PubMed ID: 30509755
    [No Abstract]   [Full Text] [Related]  

  • 34. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
    Guo NH; Zheng JF; Zi FM; Cheng J
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30455393
    [No Abstract]   [Full Text] [Related]  

  • 35. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
    Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
    Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
    Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
    Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach.
    Ji Z; Wu D; Zhao W; Peng H; Zhao S; Huang D; Zhou X
    Sci Rep; 2015 Aug; 5():13291. PubMed ID: 26282073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem and multipotent progenitor cells produce IL-17, IL-21 and other cytokines in response to TLR signals associated with late apoptotic products and augment memory Th17 and Tc17 cells in the bone marrow of normal and lupus mice.
    Chen CI; Zhang L; Datta SK
    Clin Immunol; 2016 Jan; 162():9-26. PubMed ID: 26521071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.